MULTIPLE SCLEROSIS MS

1
MULTIPLE SCLEROSIS (MS)
2
CASE STUDY

• 30 year old white female presents to family
  physician with acute loss of vision in left eye
• Referred to neurologist
• Diagnosis of optic neuritis
• Treated with IV corticosteroids for 5 days
• Normal vision over next 3 weeks
• Family history (mother)
• Magnetic resonance imaging (MRI)
• Multiple lesions in white matter of brain under
  cortex and around ventricles

3
CASE STUDY

• 3 years later
• Muscle weakness on left side of face and fatigue
• Radiology (MRI with gadolinium)
• New lesions in left middle cerebellar peduncle
  and pons
• Laboratory (CSF from lumbar puncture)
• 12 lymphocytes/uL
• IgG index of 1.2
• Oligoclonal bands (high resolution protein
  electrophoresis)
• 2 bands in gamma region of CSF and no bands in
  gamma region of serum
• Diagnosis of MS
• Treatment with 5 day course of IV
  methylprednisolone and weekly IM interferon-beta
  (Avonex)

4
CASE STUDY

• 3 years later
• Clinical symptoms
• Weakness in left hand and left leg
• Slurred speech, nystagmus, ataxia and fatigue
• Laboratory
• Myelin basic protein (serum)
• 3.4 ng/mL
• Treatment
• 5 day course of IV methylprednisolone
• Weekly IM interferon-beta (Avonex) continued

5
CASE STUDY

• Eight months later
• Clinical symptoms recurred
• Laboratory
• Myelin basic protein (serum)
• 4.1 ng/mL
• Treatment
• IFN-beta (Avonex) stopped
• High dose IV methylprednisolone and
  cyclophosphamide (Cytoxan) monthly for 3 months
  then quarterly
• Following 9 months therapy
• Asymptomatic
• No new lesions on gadolinium MRI

6
MULTIPLE SCLEROSIS (MS)

• Chronic unpredictable disease of CNS
• Tends to follow certain patterns (clinical
  courses)
• Initial symptoms 20 to 40 years
• Not contagious
• Rarely fatal
• Autoimmune disease
• Characterized by patches (plaques) of
  demyelination and inflammation of myelin sheath
  of axons and degeneration of axons in white
  matter of CNS

7
(No Transcript)
8
(No Transcript)
9
ETIOLOGY OF MULTIPLE SCLEROSIS (MS)

• Complex with multiple causal factors
• Environmental agents
• Viruses (EBV, HHV-6, measles virus, CDV)
• Bacteria (Chlamydophilia pneumoniae)
• Chemicals (organic solvents)
• UV light
• Genetic predisposition
• HLA-DR2
• Parent to child
• Geographic predisposition
• Age

10
EPIDEMIOLOGY OF MULTIPLE SCLEROSIS

• Female to male ratio of 21
• Prevalence of 11000 population
• Northern Europe
• Continental North America
• 350,000 to 400,000 in US
• Australia (SE) and New Zealand
• Incidence in US of 200 to 300 cases/week
• Disease prevalence
• Caucasians African Americans Asians

11
EPIDEMIOLOGY OF MULTIPLE SCLEROSIS (MS)

• Hemisphere gradients for prevalence
• North to south in northern hemisphere
• South to north in southern hemisphere
• Prevalence gradients in Northern Hemisphere
• North of 37th parallel (125 cases/100,000
  population)
• South of 37th parallel (70 cases/100,000
  population)
• Migration risk
• Geographic move and risk for developing disease
• Disease rare or not seen in
• Inuit, Lapps, American Indians, Aborigines, Maoris

12
(No Transcript)
13
RISK OF MULTIPLE SCLEROSIS (MS)

• A 12 year old female
• Moves from Rochester, Minnesota to
• Miami, Florida
• Risk for MS is Increased
  Decreased Same
• An 18 year old female
• Moves from Rochester, Minnesota to
• Miami, Florida
• Risk for MS is Increased
  Decreased Same

14
DIAGNOSIS OF MULTIPLE SCLEROSIS (MS)

• McDonald Criteria (2005 Revision)
• History and clinical symptoms
• Radiology
• Magnetic resonance imaging (MRI) with and without
  gadolinium enhancement
• Head and spinal column
• Laboratory
• MS panel

15
CLINICAL SYMPTOMS OF MULTIPLE SCLEROSIS (MS)

• Fatigue
• Visual disturbances
• Blurred vision, diplopia, nystagmus, red-green
  color dissociation
• Motor
• Spasticity, paresis, dysarthria, spasms, ataxia,
  muscle weakness
• Sensory changes
• Paraesthesia, neuralgia
• Cognitive deficits
• Memory loss
• Bladder / bowel urgency and incontinence

16
CLINICAL CONDITIONS ASSOCIATED WITH MS

• Optic neuritis
• Inflammation of optic nerve
• Internuclear ophthalmoplegia
• Paraylsis of ocular muscles
• Transverse myelitis
• Inflammation of spinal cord

17
(No Transcript)
18
PATTERNS (CLINICAL COURSES) OF MULTIPLE SCLEROSIS

• Relapsing-Remitting (85)
• Relaspes (attacks, exacerbations) followed by
  remission (rest periods)
• Attack symptoms (old may flare, new may appear)
• Secondary Progressive (50)
• Most common course following RR
• Primary Progressive (10)
• Older patients
• Progressive-Relapsing (5)

19
(No Transcript)
20
(No Transcript)
21
RADIOLOGY DIAGNOSIS OF MULTIPLE SCLEROSIS (MS)

• McDonald Criteria
• 3 of 4 criteria for positive MRI
• 1 gadolinium (Gd) enhancing lesion or 9 T2
  hyperintense non-Gd enhancing lesions
• 1 or more infratentorial lesions
• 1 or more juxtacortical lesions
• 3 or more periventricular lesions
• 1 brain lesion 1 spinal cord lesion

22
(No Transcript)
23
(No Transcript)
24
LABORATORY DIAGNOSIS OF MULTIPLE SCLEROSIS (MS)

• Oligoclonal bands
• CSF IgG Index
• Myelin basic protein (MBP)
• Serum reference range of
• Anti-myelin associated glycoprotein (Anti-MAG)
• IgM by IFA of

25
LABORATORY DIAGNOSIS OF MS (OLIGOCLONAL BANDS)

• Marker for intrathecal antibody synthesis
• Associated with
• MS, Sjogrens syndrome, SLE
• AIDS, Creutzfeldt-Jakob disease (CJD),
  Lyme disease, Syphilis
• Subacute sclerosing panencephalitis (SSPE)
• Guillain-Barre syndrome (GBS)
• Neoplasms

26
LABORATORY DIAGNOSIS OF MS (OLIGOCLONAL BANDS)

• Specimens
• CSF and serum
• Method
• High resolution protein electrophoresis
• Concentration of CSF (80-100 X)
• Agarose gel
• 250 V for 20 minutes
• Coomassie brilliant blue stain
• Interpretation
• 2 or more bands in gamma region of CSF and no
  bands in gamma region of serum

27
(No Transcript)
28
(No Transcript)
29
(No Transcript)
30
LABORATORY DIAGNOSIS OF MS (CSF IgG INDEX)

• CSF IgG to CSF albumin ratio compared to serum
  IgG to serum albumin ratio
• CSF IgG / CSF albumin
• serum IgG / serum albumin
• Reference value

31
TREATMENT OF MULTIPLE SCLEROSIS

• Two categories
• Symptom management agents
• Disease modifying agents
• Symptom management agents
• Corticosteroids
• Prednisone, methylprednisolone, dexamethasone
• Indicated for acute exacerbations

32
TREATMENT OF MULTIPLE SCLEROSIS

• Disease modifying agents
• Immunomodulating
• Interferon beta-1b (Betaseron)
• Interferon beta-1a (Avonex)
• Interferon beta-1a (Rebif)
• Glatiramer acetate (Copaxone)
• Natalizumab (Tysabri)
• Immunosuppressant
• Mitoxantrone (Novantrone)

33
NATALIZUMAB (TYSABRI)

• Chimeric IgG4 monoclonal antibody
• Indicated for relapsing forms of MS
• Monotherapy
• MOA
• Binds to alpha4 family of integrins on leukocytes
  (except neutrophils)
• Prevents leukocytes from leaving blood
• Receptors for alpha 4 family
• VCAM-1
• MadCAM-1

34
(No Transcript)
35
NATALIZUMAB (TYSABRI)

• FDA approval in November, 2004
• Manufacturer withdrawal in February, 2005
• Adverse event (Boxed Warning)
• Increased risk of
• Progressive multifocal leukoencephalopathy (PML)
• PML
• Viral encephalitis caused by JC virus
• FDA reapproval in March, 2006

36
INTERFERON BETA-1b (BETASERON)

• Protein from human interferon beta-1b gene on
  plasmid in Escherichia coli
• Serine for cysteine at 17
• Indications
• Relapsing forms
• Initial clinical episode with MRI
• Mechanism of action is unknown
• Administration
• Subcutaneous injection every other day

37
INTERFERON BETA 1a (AVONEX)

• Glycoprotein from human interferon beta-1a gene
  in Chinese Hamster Ovary Cells
• Indications
• Relapsing forms
• Mechanism of action is unknown
• Beta 2 microglobulin
• Neopterin
• Dose and administration
• 30 mcg IM / week

38
INTERFERON BETA 1a (REBIF)

• Glycoprotein from human interferon beta-1a gene
  in Chinese Hamster Ovary Cells
• Indications
• Relapsing forms
• Mechanism of action is unknown
• Beta 2 microglobulin
• Neopterin
• Dose and administration
• 22 mcg or 44 mcg SC 3x /week

39
DIFFERENCE BETWEEN AVONEX AND REBIF

• 
  Patients
• Avonex
  Rebif
• Relapse free (24 w) 63
  75
• Relapse free (48 w) 52
  62
• Injection site reactions 33
  85

40
MECHANISM OF DISEASE IN MULTIPLE SCLEROSIS

• Type IV autoimmune mechanism
• Targets
• Myelin, oligodendrocytes, nerve axons
• Cells
• CD4TH1 cells, macrophages, B cells, CD8 cells
• Blood, CSF and myelin plaques
• Autoantigens in myelin
• Myelin basic protein (MBP), myelin
  oligodendrocyte glycoprotein (MOG)
• Cytokines, chemokines and adhesion molecules
• IL-12, IFN-gamma and B7.1

41
(No Transcript)